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Abstract
Background: Neisseria gonorrhoeae (N. gonorrhoeae) resistance to antimicrobial has been a major concern in China,
and epidemiological data on N. gonorrhoeae resistance are not well understood. This meta-analysis was aimed at
summarizing the evidence on N. gonorrhoeae resistance to penicillin, tetracycline, ciprofloxacin, ceftriaxone and
spectinomycin in China.
Methods: Two researchers independently searched five databases to identify studies on N. gonorrhoeae resistance to
antimicrobials from the databases’ inception to November 7, 2014. A random-effects model was used to estimate the
antimicrobial resistance rates and their corresponding 95 % confidence intervals (CIs). Publication bias was assessed
with the Begg rank correlation test and the Egger test.
Results: We included 127 studies in our synthesis reporting antimicrobial resistance. Our analyses demonstrated that N.
gonorrhoeae resistance to penicillin and tetracycline respectively increased from 74.41 % (95 % CI: 64.1–84.7 %) and
68.3 % (95 % CI: 58.7–78.0 %) in 2000 to 84.2 % (95 % CI: 79.7–88.8 %) and 82.4 % (95 % CI: 79.9–84.7 %) in 2012. N.
gonorrhoeae resistance to ciprofloxacin experienced a steady increase from 12.7 % (95 % CI, 8.6–16.7 %) in 1995 and
reached 93.8 % (95 % CI: 91.9–95.7 %) in 2003. N. gonorrhoeae resistance to ceftriaxone was 1.7 % (95 % CI: 0.5–5.7 %)
before 1995 and 0.5 % (95 % CI: 0.2–1.4 %) in 2012, and N. gonorrhoeae resistance to spectinomycin was less than 2 %
from 1995 to 2012.
Conclusions: N. gonorrhoeae resistance rates to penicillin, tetracycline and ciprofloxacin were high in China.
Ceftriaxone and spectinomycin remained effective therapy for the treatment of gonorrhea. It is essential to strengthen
N. gonorrhoeae resistance surveillance and update treatment guidelines timely.
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Background
Neisseria gonorrhoeae (N. gonorrhoeae) is the causative
agent of gonorrhea, which is one of the most prevalent
sexually transmitted diseases (STD) and causes male ur-
ethritis, female endocervicitis, and severe reproductive
complications. It also increases the transmission of hu-
man immunodeficiency virus, resulting in substantial
morbidity and socioeconomic consequences [1]. The
World Health Organization (WHO) estimated 106 mil-
lion new cases of gonorrhea worldwide in 2008 [2, 3]. In
China, patients with N. gonorrhoeae visited STD clinics or
hospital outpatient departments for treatment and 95,263
cases of gonorrhea were reported in 2012, making gonor-
rhea the sixth most common infectious disease [4] and the
first most common STD [5].
Management of N. gonorrhoeae infection is a serious
challenge in the setting of increasing antimicrobial resist-
ance (AMR) [6–8]. The importance of AMR surveillance
has been extensively elucidated [9, 10], particularly as
treatment options for gonorrhea decreased because of the
spread of resistance to sulfonamides, penicillin, tetracyc-
line, and quinolone.
China established a national surveillance program to
monitor AMR in 1987. Twenty-five N. gonorrhoeae
AMR surveillance sentinel sites were distributed in 25
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provinces of China based on the medical resource distri-
bution and geographical representativeness, which were
established by the Chinese Center for Disease Control and
Prevention (CDC). N. gonorrhoeae resistance cases were
sent to Chinese CDC by sentinel sites. Since 1992, China
has been a part of WHO Western Pacific Regional (WPR)
Gonococcal Antimicrobial Surveillance Programme. How-
ever, we found that only two studies reported N. gonor-
rhoeae resistance to antimicrobials based on nationwide
data from the surveillance program [11, 12]. Whereas,
more than a hundred reports on N. gonorrhoeae AMR
were based on data from one or a few surveillance sentinel
sites, and these studies had obvious differences in settings,
methods, findings, and some other characteristics. We
conducted this systematic review in order to provide a
comprehensive understanding of N. gonorrhoeae resist-
ance to antmicrobials in China.
Methods
This meta-analysis was conducted according with the
checklist of the Meta-Analysis of Observational Studies
in Epidemiology Guideline [13].
Search strategy
Two independent researchers (Y.W.C and T.T.Y) searched
four Chinese biomedical databases (China Biology
Medicine disc [CBMdisc] (1978–), China National
Knowledge Infrastructure [CNKI] (1915–), VIP Infor-
mation/Chinese Scientific Journals database (1989–)
and Wanfang database (1998–)) and PubMed (1966–)
to identify relevant studies from their respectively
inception to November 7, 2014. Search terms (in
Chinese) included “Neisseria gonorrhoeae” or “gonor-
rhea”, and their combinations with “resistant” or “re-
sistance” or “susceptible” or “susceptibility” in Chinese
databases. We used the string ‘(Neisseria gonorrhoeae
or gonococc* or gonorrh*) AND (resistan* or sensitiv*
or susceptib*) AND (China or Chinese)’ in PubMed.
In addition, relevant references from each study were
retrieved and further added to the analysis.
Inclusion criteria
The included studies met the following criteria: (1) an ori-
ginal study published in Chinese or English; (2) conducted
in mainland China; (3) determined minimum inhibitory
concentrations (MICs) by using the agar dilution method;
(4) specified the total number of tested N. gonorrhoeae iso-
lates; (5) reported the AMR rate in N. gonorrhoeae isolates,
or implied it by indicating their MICs, following the criteria
by WHO WPR Resistance Surveillance Programme guide-
lines[14] or Clinical and Laboratory Standards Institute
standards; (6) tested more than 30N. gonorrhoeae isolates
in order to guarantee the quality of testing; and (7) isolated
N. gonorrhoeae strains from adults (age ≥18 years).
Data extraction
The following data was extracted from each study: name
of first author, publication year, study region, number of
tested isolates, and resistance rate. Data from the included
studies were independently extracted by two authors
(X.Y.S and J.L) and any discrepancies were resolved
through the introduction of a third reviewer (X.X.Y).
Quality assessment
The methodological quality of the included studies was
assessed with the recommended approach of the WHO
[15]. Briefly, we assessed (1) whether the study described
the method of identifying N. gonorrhoeae isolates;(2)
whether the study specified the location where N. gonor-
rhoeae isolates were collected;(3) whether the study speci-
fied the collection period of the isolates; (4) whether the
study described the population from which N. gonorrhoeae
isolates were obtained;(5) whether the study included at
least 100 tested N. gonorrhoeae isolates;(6) whether the
study utilized control strains recommended by WHO in
determining MICs with agar dilution method.
The quality assessment scores of the included studies
are shown in Additional file 1: Table S1. Each criterion
was rated 1 point if a study satisfied the WHO’s recom-
mendation. Two independent reviewers assessed the
quality of the included studies. We considered studies
that scored 5 or higher as “high quality”, 3 or 4 as “mod-
erate quality”, and 2 or lower as ‘low quality’.
Statistical analysis
N. gonorrhoeae resistance rates to antimicrobials with
their corresponding 95 % confidence intervals (CIs) were
calculated using the random-effects model. Where a
study reported results for years separately, these were
regarded as separate reports. Subgroup analyses were
carried out by year. If the number of reports in 1 year
was less than 3, these reports were subsumed in the next
year. For example, only one report about N. gonorrhoeae
resistance to tetracycline in 2002; thus, we subsumed
this report in 2003 to conduct a meta-analysis. In our
study, considering that reports published before 1995
and after 2012 were scarce and the number of reports
was less than 3 in any year before 1995 and after 2012,
we have subsumed the reports published before 1995
and after 2012 in one subgroup to make our results
more understandable.
Statistical heterogeneity among studies was evaluated
by using the I2 statistic, where values of 25, 50 and 75 %
represent cut-off points for low, moderate and high de-
grees of heterogeneity, respectively [16]. Publication bias
was assessed by using the Begg test [17] and the Egger
test [18]. All statistical analyses were performed by using
Comprehensive Meta Analysis V3. All tests were two-
sided with a significance level of 0.05.
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Results
Literature search
We present the study selection process in Fig. 1. The
search identified 5,607 unique articles from PubMed,
CNKI, CBMdisc, VIP, and WanFang, of which 270 were
identified as potentially relevant. After retrieving the full
text for further evaluation, 127 studies that reported N.
gonorrhoeae AMR rates were included.
Study characteristics
The main study characteristics and quality assessment re-
sults are shown in Additional file 1: Table S1. Of the127
studies (Additional file 2: Table S2), 12 were in English
and 115 were in Chinese. These studies were published
between 1991 and 2014. In these studies, 42,509N. gonor-
rhoeae isolates were examined for their resistance to one
or more antimicrobials used for the treatment of gonor-
rhea. Of the 127 studies, 90 were deemed high-quality
studies; 34, moderate-quality studies; and 3, low-quality
studies. The N. gonorrhoeae resistance rates to penicillin,
tetracycline, ciprofloxacin, ceftriaxone and spectinomycin
were estimated in our study.
N. gonorrhoeae resistance to antimicrobials
In 91 studies, 154 reports were found on N. gonorrhoeae re-
sistance to penicillin. The pooled N. gonorrhoeae resistance
rate to penicillin was 58.1 % (95 % CI: 50.3–65.8 %) before
1995 and increased up to 84.2 % (95 % CI: 79.7–88.8 %) in
2012 (Fig. 2).
According to 73 reports, the N. gonorrhoeae resistance
rate to tetracycline fluctuated over time. The resistance
rate was 68.3 % (95 % CI: 58.7–78.0 %) before 2003 and
picked in 2008 (91.7 %, 95 % CI: 86.4–97.0 %; Fig. 2). Be-
tween 1994 and 2013, 221 reports from 113 studies were
about N. gonorrhoeae resistance to ciprofloxacin. The N.
gonorrhoeae resistance rate to ciprofloxacin reached
93.8 % (95 % CI: 91.9–95.7 %) in 2003 and fluctuated be-
tween 92.1 % (95 % CI: 90.1–94.0 %) and 99.3 % (95 %
CI: 98.9–99.7 %) between 2004 and 2012 (Fig. 2).
In 103 studies, 205 reports estimated N. gonorrhoeae re-
sistance to ceftriaxone. The pooled resistance rate was
1.7 % (95 % CI: 0.5–5.7 %) before 1995 and 0.5 % (95 % CI:
0.2–1.4 %) in 2012 (Fig. 2). N. gonorrhoeae resistance to
spectinomycin was reported in 113 studies, with 33,485N.
gonorrhoeae isolates. The pooled N. gonorrhoeae resistance
rate to spectinomycin was 0.3 % (95 % CI: 0.2–0.8 %; Fig. 2).
Data on N. gonorrhoeae resistance to antimicrobials are
shown in Additional file 3: Table S3.
Publication bias
Evidence of high heterogeneity was observed for each
antimicrobial agent in our study (I2 ranged from 64.89
to 95.80 %, P = 0.001). The Begg rank correlation test
and Egger linear regression test indicated evidence of
Fig. 1 Process of selecting published studies for the meta-analysis
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publication bias among studies for each antimicrobial
agent (P < 0.05 for both tests); Additional file 4: Table S4).
Discussion
Based on data from 127 studies, including 42,509 tested
N. gonorrhoeae isolates, N. gonorrhoeae resistance to the
previously recommended first-line antimicrobials peni-
cillin, tetracycline and ciprofloxacin reached as high as
84.2, 71.3, and 96.3 %, respectively, in China. The N.
gonorrhoeae resistance rates to penicillin and tetracycline
were higher in China than in other Asian countries such
as Vietnam [9], India, Pakistan and Bhutan [19] during
the same period. Ciprofloxacin-resistant N. gonorrhoeae
isolates in China were much higher than those reported
in Laos [20–22] and Vietnam [20–26], and were com-
parable with those in Thailand [9, 27, 28]. N. gonor-
rhoeae resistance rate to spectinomycin remains very
low, which is in accordance with WHO report [29] and
previous studies from other countries in the Western
Pacific Region [30–33].
The WHO recommends that routine use of an anti-
microbial for treatment should be discontinued when
therapeutic failure and/or AMR rate reaches a level of 5 %
[34]. The unremitting development of resistance to mul-
tiple antimicrobials in N. gonorrhoeae isolates has moti-
vated ongoing modification of treatment guidelines in
China. Penicillin was recommended as the first choice of
treatment of N. gonorrhoeae infections in 1989. By 1995,
the N. gonorrhoeae resistance rate to penicillin was nearly
60 %. The recommended treatment of gonorrhea was then
changed to ciprofloxacin in 1995. Afterwards, the N.
gonorrhoeae resistance rate to ciprofloxacin increased
sharply and reached 79.4 % by 2000. Many studies suggest
that the widespread use of antimicrobials was an import-
ant cause in the development of AMR [35–38]. We
hypothesize that N. gonorrhoeae AMR might be contrib-
uted to the widespread use of penicillin and ciprofloxacin
after they have been recommended for clinical use. In
response to extensive N. gonorrhoeae resistance to penicil-
lin and ciprofloxacin, ceftriaxone and spectinomycin were
recommended as the first-line antimicrobials for the treat-
ment of gonorrhea in 2000 in China. Fortunately, accord-
ing to our data, N. gonorrhoeae resistance to both
ceftriaxone and spectinomycin is not widespread. The N.
gonorrhoeae resistance rates to ceftriaxone and spectino-
mycin were 0.5 and 0.3 %, respectively, in 2012.
The main reason for the rapid increase of N. gonorrhoeae
resistance rates to penicillin and ciprofloxacin after they
have been recommended for clinical use is likely their indis-
criminate use. Gonorrhea was considered to be caused by
the sexual misconduct in China in the 1990s; and because
of stigma, patients trended to administer antimicrobial
treatment by themselves or visited non-formal medical in-
stitutions such as unregistered private clinics. Moreover,
some patients did not complete the full treatment course,
increasing the chance for AMR to develop. In addition, at
Fig. 2 N. gonorrhoeae resistance to penicillin, tetracycline, ciprofloxacin, ceftriaxone and spectinomycin, 1995–2012
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the time, antimicrobial management policies and effective
supervision over physicians’ prescribing behaviors were
lacking in China. For example, patients could buy antimi-
crobials in drug stores without a prescription. Indeed, an
association between self-prescribed antimicrobial use and
gonococcal AMR was observed in Philippines [39].
Recognizing the rapid spread and serious consequences
of AMR [40], the Ministry of Health of China promul-
gated “The Guidelines on the Clinical Application of Anti-
microbials” in 2004 and “The Guidelines on Prescription
Management” in 2006. The Ministry also issued “Prescrip-
tion Management and Evaluation Standards in Clinical
Practice” in 2010. For STDs, the Chinese CDC formu-
lated “The Guidelines for Diagnosis and Treatment of
Sexually Transmitted Disease” in 2006; the Ministry of
Health modified and promulgated “Prevention and
Management of Sexually Transmitted Disease” in 2012,
which defined legal responsibility for relevant depart-
ments and personnel, and explicitly stated that medical
institutions should further standardize the treatment of
gonorrhea. In addition, the government strengthened
health education on the importance of timely and stan-
dardized treatment of gonorrhea. These measures may
have potentially contributed to the low resistance rates
to ceftriaxone and spectinomycin. However, given that
treatment failures with ceftriaxone have been reported
not only in China [41–43] but also in Japan, France, and
Spain [44–46], and spectinomycin-resistant N. gonor-
rhoeae strains have been detected in China [47–51] and
other countries [52, 26], clinicians should closely monitor
for the resistance status of patients treated with ceftriax-
one and spectinomycin.
Our study has a number of limitations: (1) the in-
cluded studies were conducted in various regions, mostly
with variable sample sizes, which introduced substantial
heterogeneity to the data obtained; (2) all tested N.
gonorrhoeae isolates were collected from patients who
attended STD clinics or hospital outpatient departments,
which may introduce sample bias for the patients may
have a higher prevalence of N. gonorrhoeae AMR than
the general population; and (3) demographic information
such as sex and age and information regarding “risk pa-
tient groups” or “risk factors” were lacking.
Conclusions
N. gonorrhoeae resistance rates to penicillin, tetracycline
and ciprofloxacin were high in China, while the resistance
rates to ceftriaxone and spectinomycin remained lower
than 5 %. Therefore, ceftriaxone and spectinomycin can
be recommended as effective therapy for gonorrhea in
China. Nevertheless, considering the emergency of ceftrix-
one and spectinomycin resistant strains in various regions,
it is essential to strengthen N. gonorrhoeae resistance
surveillance and update treatment guidelines timely based
on new evidence as antimicrobial resistance develops.
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